Adenoviral reporter gene transfer to the human trabecular meshwork does not alter aqueous humor outflow.: Relevance for potential gene therapy of glaucoma

被引:58
作者
Borrás, T
Rowlette, LL
Erzurum, SC
Epstein, DL
机构
[1] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA
[2] Cleveland Clin Fdn, Cleveland, OH 44195 USA
关键词
gene therapy; glaucoma; adenoviral vectors; aqueous humor outflow facility; trabecular meshwork;
D O I
10.1038/sj.gt.3300860
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Obstruction of the aqueous humor outflow from the anterior chambers of the eye leads to an elevation of intraocular pressure in glaucoma, the second major cause of blindness world-wide. Our goal is to be able to modulate aqueous humor outflow resistance by gene transfer to the cells of the trabecular meshwork (TM). We have previously shown that adenoviral vectors are able to transfer a reporter gene to the TIW of post-mortem human donors. However, assessing gene therapy for glaucoma requires models that can monitor changes in aqueous humor outflow facility (C=flow/pressure). In this study we used four replication-deficient adenoviruses in two such perfusion models. In the first model, whole porcine eyes were infected, perfused at constant pressure and flow changes recorded for 5 h. In the second one, anterior segments from human eyes were infected, perfused at constant flow and pressure changes recorded for 3 days. A single dose of 10(8) adenovirus plague forming units (pfu) causes a reduction in C while single doses of 10(7), 10(6) and 10(5) p.f.u. do not affect outflow facility and retain positive gene transfer. These findings indicate that adenovirus, at effective doses, could become useful vectors for gene therapy of glaucoma.
引用
收藏
页码:515 / 524
页数:10
相关论文
共 53 条
  • [1] ABRAHAM NG, 1995, INVEST OPHTH VIS SCI, V36, P2202
  • [2] ALEXANDER JP, 1991, INVEST OPHTH VIS SCI, V32, P172
  • [3] BARANY ERNST, 1959, DOCUMENTA OPHTHALMOL, V13, P41, DOI 10.1007/BF00157907
  • [4] BENNETT J, 1994, INVEST OPHTH VIS SCI, V35, P2535
  • [5] BERKNER KL, 1988, BIOTECHNIQUES, V6, P616
  • [6] BILL A, 1975, INVEST OPHTH VISUAL, V14, P1
  • [7] Borras T, 1998, INVEST OPHTH VIS SCI, V39, P1503
  • [8] Borras T, 1996, INVEST OPHTH VIS SCI, V37, P1282
  • [9] BUDENZ DL, 1995, INVEST OPHTH VIS SCI, V36, P2211
  • [10] Channon KM, 1996, CARDIOVASC RES, V32, P962